Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Key Research Areas Gastrointestinal mucosal protection BPC-157 is studied in gut tissue models for its interaction with gastric mucosal repair pathways, including protection against NSAID-induced lesions and inflammatory bowel disease models Tendon and ligament biology Investigated in in-vitro and rodent models for its influence on fibroblast activity, collagen synthesis, and tendon-to-bone attachment repair Angiogenesis Studied for its promotion of VEGF expression and new blood vessel formation in wound healing and ischaemia models Neuroprotection Referenced in studies examining dopamine and serotonin system modulation
Regulatory framing remains research-use-only
Herrington WG, Staplin N, Wanner C et al (2023) Empagliflozin in patients with chronic kidney disease
GLP-1 medications slow digestion, so food stays in your stomach longer
The strong result comes after Lilly posted equally impressive results with retatrutide in people living with overweight/obesity and knee osteoarthritis in the TRIUMPH-4 study, and in type 2 diabetes patients in the TRANSCEND-T2D-1 trial, building the case for the drug as one of the major new medications in the cardiometabolic category
